Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
March 14, 2023 16:05 ET
|
Arbutus Biopharma Corporation
Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses WARMINSTER, Pa., March 14,...